1. Home
  2. STTK vs ULBI Comparison

STTK vs ULBI Comparison

Compare STTK & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • ULBI
  • Stock Information
  • Founded
  • STTK 2016
  • ULBI 1990
  • Country
  • STTK United States
  • ULBI United States
  • Employees
  • STTK N/A
  • ULBI N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • ULBI Industrial Machinery/Components
  • Sector
  • STTK Health Care
  • ULBI Miscellaneous
  • Exchange
  • STTK Nasdaq
  • ULBI Nasdaq
  • Market Cap
  • STTK 37.6M
  • ULBI 150.0M
  • IPO Year
  • STTK 2020
  • ULBI 1992
  • Fundamental
  • Price
  • STTK $0.79
  • ULBI $8.80
  • Analyst Decision
  • STTK Hold
  • ULBI Strong Buy
  • Analyst Count
  • STTK 4
  • ULBI 1
  • Target Price
  • STTK $3.00
  • ULBI $14.00
  • AVG Volume (30 Days)
  • STTK 470.6K
  • ULBI 175.8K
  • Earning Date
  • STTK 07-31-2025
  • ULBI 07-24-2025
  • Dividend Yield
  • STTK N/A
  • ULBI N/A
  • EPS Growth
  • STTK N/A
  • ULBI N/A
  • EPS
  • STTK N/A
  • ULBI 0.31
  • Revenue
  • STTK $4,606,000.00
  • ULBI $173,275,000.00
  • Revenue This Year
  • STTK N/A
  • ULBI $31.30
  • Revenue Next Year
  • STTK N/A
  • ULBI $6.24
  • P/E Ratio
  • STTK N/A
  • ULBI $27.75
  • Revenue Growth
  • STTK 69.65
  • ULBI 2.74
  • 52 Week Low
  • STTK $0.69
  • ULBI $4.07
  • 52 Week High
  • STTK $4.99
  • ULBI $12.40
  • Technical
  • Relative Strength Index (RSI)
  • STTK 39.92
  • ULBI 60.73
  • Support Level
  • STTK $0.75
  • ULBI $8.45
  • Resistance Level
  • STTK $0.85
  • ULBI $8.91
  • Average True Range (ATR)
  • STTK 0.08
  • ULBI 0.36
  • MACD
  • STTK -0.01
  • ULBI -0.10
  • Stochastic Oscillator
  • STTK 10.56
  • ULBI 57.93

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Share on Social Networks: